Risk factors and prognosis of checkpoint inhibitor pneumonitis
10.13406/j.cnki.cyxb.003844
- VernacularTitle:免疫检查点抑制剂相关性肺炎的风险因素和预后
- Author:
Hong XIE
1
;
Jun WANG
Author Information
1. 山东第二医科大学临床医学院,潍坊 261000
- Keywords:
immunotherapy;
immune checkpoint inhibitors;
immune-related adverse events;
checkpoint inhibitor pneumonitis;
risk factors;
biomarkers;
diagnosis
- From:
Journal of Chongqing Medical University
2025;50(6):734-741
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors(ICIs)have been widely used in the treatment of advanced solid tumors and have brought good clinical benefits.However,while ICIs can activate immune response in the body to exert an antitumor effect,they can also cause inflammatory response in multiple organ systems throughout the body,known as immune-related adverse events(irAEs).Checkpoint inhibitor pneumonitis(CIP)is one of severe irAEs,which can affect the efficacy of immunotherapy and even be life-threatening.There-fore,identifying the risk factors for CIP and exploring related predictive markers are of great importance for the pre-treatment assess-ment and whole-course monitoring and treatment of patients with solid tumors receiving ICIs.This article summarizes the research ad-vances in CIP,including incidence rate,risk factors,treatment,and prognosis,and discusses the biomarkers for the clinical manage-ment and prediction of CIP,in order to provide a reference for clinical diagnosis and mechanism studies.
